News

PeproMene Bio's Innovative BAFFR-CAR T Therapy Presents Key Data

PeproMene Bio's Innovative BAFFR-CAR T Therapy Presents Key Data

PeproMene Bio Shows Promising Progress with PMB-CT01

IRVINE, Calif. — PeproMene Bio, Inc., a notable clinical-stage biotechnology firm focused on advancements in treatment for relapsed and refractory B-cell malignancies, has achieved a significant milestone. Two abstracts from the ongoing Phase 1 trials of PMB-CT01, a BAFFR-CAR T therapy, have been accepted for oral presentations at a prestigious annual meeting.

Key Findings on PMB-CT01

The abstracts present valuable insights into the safety and efficacy of PMB-CT01, particularly among patients with heavily pretreated relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma (B-NHL). These findings highlight PMB-CT01's effectiveness in patients who either did not respond to prior CD19 therapies or have CD19-negative disease, revealing a differentiated target that could overcome CD19 antigen escape. The interim results from the Phase 1 dose-escalation studies show promising safety profiles alongside effective results.

Insights on r/r B-NHL

Safety Profile: The PMB-CT01 therapy demonstrated a remarkable tolerability with no cases of Grade >1 Cytokine Release Syndrome (CRS) and no Grade >1 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) reported.

Efficacy: All seven initial patients experienced a Complete Response (CR) within 1 to 3 months following the infusion, including those who had undergone previous CD19-directed therapies and those with CD19-negative status.

Durability of Response: The patients' remissions have continued for over 32 months, with a median duration of 17 months as confirmed during data analysis.

Highlights of r/r B-ALL

Efficacy: Among six patients enrolled, four achieved an undetectable Minimal Residual Disease (MRD-) CR, a notable accomplishment in this high-risk population.

High-Risk Achievements: Three of the four responders were CD19-negative at the start of the trial and successfully proceeded to allogeneic hematopoietic cell transplant with curative intent.

Safety Measures: No Dose-Limiting Toxicities (DLTs) were found during the study, with only one patient experiencing Grade 2 CRS while there were no reports of Grade 3 CRS.

The Future of B-cell Malignancy Treatments

Dr. Hazel Cheng, COO of PeproMene Bio, expressed optimism regarding the data. She stated, "The consistent and durable performance across both types of B-cell malignancies, especially in patients with exhausted CD19 options, underscores BAFF-R's potential as a safe and highly effective therapeutic alternative. This data emphasizes the capability of PMB-CT01 to meet critical unmet medical needs in high-risk relapsed disease scenarios."

Details of the ASH 2025 Presentations

PeproMene Bio will present two abstracts at the ASH 2025 Annual Meeting:

  • Abstract Title: BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas…
    Abstract Reference: abs25-7079
    Date/Time: December 6, 2:45 PM
    Presenter: Elizabeth Budde, M.D., Ph.D.
  • Abstract Title: BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients…
    Abstract Reference: abs25-2035
    Date/Time: December 8, 11:00 AM
    Presenter: Ibrahim Aldoss, M.D.

About PMB-CT01 Therapy

PMB-CT01 stands out as a pioneering BAFF-R–targeted autologous CAR T cell therapy, primarily targeting B cells essential for survival. This therapy aims to limit the chance of antigen-loss escape while being thoroughly investigated in its Phase 1 trials aimed at treating r/r B-NHL and r/r B-ALL.

Frequently Asked Questions

What is PMB-CT01?

PMB-CT01 is an innovative CAR T cell therapy targeted at BAFF-R, which is crucial for the survival of B cells.

What conditions does PMB-CT01 aim to address?

PMB-CT01 focuses on treating relapsed and refractory B-cell malignancies, particularly B-ALL and B-NHL.

What were the outcomes presented at the ASH 2025 Meeting?

The outcomes highlighted the safety, efficacy, and durability of responses in patients treated with PMB-CT01.

Who will present the abstracts at ASH 2025?

Elizabeth Budde and Ibrahim Aldoss, both notable doctors in their fields, will present at the conference.

What does the future hold for B-cell malignancy therapies?

The continued development of therapies like PMB-CT01 holds significant promise for improving outcomes in B-cell malignancies, particularly in high-risk patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

USPS Rolls Out Christmas Cookie Stamps Nationwide

Updated Category News Views 5

USPS Delivers Nostalgia with Cookie-Themed Stamps Let's talk stamps, folks. The U.S. Postal Service has rolled out its newest Christmas Cookies Forever stamps, bringing a dash of sugary nostalgia to mailboxes nationwide. The release was celebrated at the Smithsonian National Postal Museum, spotlighting a tradition as sweet as the sugar cookies themselves. These aren't...

Continue Reading
Med Spa Visits: Key Insights from Lindsey Smith

Updated Category News Views 4

Moving Beyond the Fear Factor Stepping into a med spa for the first time can be nerve-wracking, especially if you're unsure of what to expect. Lindsey Smith, an expert from Flawless Med Spa in Bryant, Arkansas, knows just how critical it is to navigate this terrain with clarity. Her approach emphasizes building a foundation of trust and understanding from the get-go. Fear...

Continue Reading
Why Liver Nurture Taps into Health Sector Trends

Updated Category News Views 5

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Continue Reading
Tragedy Highlights Need for E-bike Safety Overhaul

Updated Category News Views 5

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...

Continue Reading
Insta360 Expands with Times Square Flagship Store

Updated Category News Views 7

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

Continue Reading
Flying Car Regulatory Sandbox Begins in UAE

Updated Category News Views 9

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Continue Reading
BarrelPick.com Launches for Bourbon Aficionados

Updated Category News Views 4

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

Continue Reading
Papa John's Faces Class Action Over Misleading Info

Updated Category News Views 5

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Continue Reading
Qatar Foundation Spurs Sport-Driven Empowerment Moves

Updated Category News Views 4

Here we go, diving into the serious talk of the moment: sports pushing boundaries to uplift society's underdogs. Envision yourself in the halls of Wilton Park, where the thinkers, the dreamers, and the doers convened in the name of change. Qatar Foundation ain't just sitting pretty; they're championing the cause to harness sport for impactful social threads across the...

Continue Reading

Top 5 Most Recently Viewed Articles

Elon Musk's Directive Aims to Enhance Executive Branch Efficiency

Updated Category News Views 293

Elon Musk's New Email Directive for Government Employees Elon Musk‘s Department of Government Efficiency (DOGE) is taking steps to improve accountability within the executive branch by sending out directives that encourage employee engagement. A recent email has been sent to all federal employees requiring them to highlight their weekly achievements, which is part of an...

Continue Reading
Eclypsium Secures $45 Million to Strengthen Supply Chain Security

Updated Category News Views 231

Eclypsium Secures $45 Million in Series C Funding Eclypsium, a prominent player in infrastructure supply chain security, has achieved a significant milestone by securing $45 million through an oversubscribed Series C funding round. This new capital infuses equity and debt, and notably attracts investments from acclaimed entities such as Qualcomm Ventures, Pavilion...

Continue Reading
Kaldvik AS Announces Successful Subsequent Offering Results

Updated Category News Views 177

Overview of Kaldvik AS Subsequent Offering Kaldvik AS recently concluded its subsequent offering, as detailed in stock exchange announcements. This offering included the provision of up to 4,300,000 new shares, each valued at NOK 0.10, with a subscription price set at NOK 14 per share. With the subscription period officially ending, the company received notable interest...

Continue Reading
Joseph Bracco Stepped Up as Executive VP at Miami International

Updated Category News Views 381

Leadership Changes at Miami International Holdings Miami International Holdings, Inc. (MIH), a leader in the technology-driven financial markets, has announced an important leadership change. Joseph Bracco has been promoted to Executive Vice President and Global Head of Sales. This strategic move is a testament to his significant contributions since joining the firm in...

Continue Reading
ADC Therapeutics Grants Stock Options to New Employees

Updated Category News Views 57

ADC Therapeutics Grants Stock Options to New Employees ADC Therapeutics SA (NYSE: ADCT), a prominent player in the field of antibody drug conjugates, has recently made an important announcement regarding its workforce. In line with its commitment to enhancing employee performance, the company has granted stock options for a total of 17,900 shares of its common stock to...

Continue Reading